BackSunshine Biopharma Overview

Sunshine Biopharma Other Assets

Track Sunshine Biopharma's other assets ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$0.00

Peer average

Loading

Sunshine Biopharma Other Assets History

Loading

Sunshine Biopharma vs. peers: Other Assets Comparison

Loading

Sunshine Biopharma Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Sunshine Biopharma (SBFM) FAQ

Sunshine Biopharma posts a other assets of $0 as of March 2026. In the prior-year period, the figure was $0. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Sunshine Biopharma's other assets was $0. The latest reading is $0 (period ending March 2026). Use the history and growth charts on this page for a longer lookback.

Other Assets is one piece of Sunshine Biopharma's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for SBFM's other assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Sunshine Biopharma's other metric pages and overview cover the third.

Judging Sunshine Biopharma against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in other assets easier to interpret. Start with $0 here, then scan peer and history charts to see if the gap is persistent.